Methotrimeprazine (Levomepromazin)

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Nozinan; Belgium: Nozinan; Czech Republic: Tisercin; Denmark: Nozinan; Finland: Levozin, Nozinan; France: Nozinan; Germany: Levium, Levomepromazin, Neurocil; Greece: No-Calm, Nozinan; Hungary: Tisercin; Ireland: Nozinan; Italy: Nozinan; Latvia: Tisercin; Lithuania: Tisercin; Luxembourg: Nozinan; Netherlands: Levomepromazine, Nozinan; Poland: Tisercin; Portugal: Nozinan; Romania: Levomepromazin; Slovakia: Tisercin; Slovenia: Nozinan; Spain: Sinogán; Sweden: Nozinan; UK: Nozinan.

North America

Canada: Apo-Methoprazine, Methotrimeprazine, Novo Meprazine, Nozinan.

Latin America

Argentina: Detenler, Levolam, Levomepromazina, Nozinan, Sunonix, Togrel; Brazil: Levozine-Cristália, Neozine; Mexico: Levocina.


Japan: Hirnamin, Levohalte, Levotomin, Sofmin.

Drug combinations


Methotrimeprazine: C~19~H~24~N~2~OS. Mw: 328.47. (1) 10H-Phenothiazine-10-propanamine, 2-methoxy-N,N,b-trimethyl-, (-)-; (2)(-)-10-[3-(Dimethylamino)-2-methylpropyl]-2-methoxyphenothiazine. CAS-60-99-1.

Pharmacologic Category

Analgesics and Antipyretics, Miscellaneous. Non-opioid Analgesic. (ATC-Code: N05AA02).

Mechanism of action

Dopamine antagonist. Also binds α~1~-, α~2~-adrenergic, and serotonin receptors.

Therapeutic use

Treatment of schizophrenia or psychosis. Management of pain, including pain caused by neuralgia or cancer. Adjunct to general anesthesia. Management of nausea and vomiting. Sedation.

Pregnancy and lactiation implications

Unlabeled use

Bipolar disorder, agitation.


Hypersensitivity to methotrimeprazine, phenothiazines, or any component of the formulation. Severe cardiac or hepatic disease. Hematologic disorders (blood dyscrasia). History of convulsive disorders. Severe CNS depression or coma. Concurrent use of MAOIs.

Warnings and precautions

Might alter cardiac conduction. Phenothiazines might cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention) and should be used with caution in decreased GI motility, urinary retention, BPH, xerostomia, or visual problems. Might cause CNS depression. Might cause extrapyramidal symptoms and/or tardive dyskinesia. Might be associated with neuroleptic malignant syndrome. Might cause orthostatic hypotension (use with caution in cardiovascular disease or cerebrovascular disease). Hypotension might occur (particularly when parenteral form is used or in high dosages). Might alter temperature regulation. Use with caution in bone marrow suppression, in severe cardiac disease, in hemodynamically unstable patients, in severe hepatic impairment, in Parkinson’s disease, in breast cancer or other prolactin-dependent tumors (might elevate prolactin levels), in severe renal impairment, in respiratory disease, and in predisposition to seizures. Effects might be potentiated when used with other sedative drugs or ethanol.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart